https://orcid.org/0009-0008-3266-8765
References
- Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
- Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2(1):16082. doi:10.1038/nrdp.2016.82
- Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
- Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-3
- Chiricozzi A, Caposiena D, Garofalo V, Cannizzaro MV, Chimenti S, Saraceno R. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Rev Clin Immunol. 2016;12(3):237–249. doi:10.1586/1744666X.2016.1134319
- Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23–32. doi:10.1007/s40257-017-0302-0
- Mahil SK, Smith CH. Psoriasis biologics: a new era of choice. Lancet. 2019;394(10201):807–808. doi:10.1016/S0140-6736(19)31772-6
- Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs. 2014;74(7):825–837. doi:10.1007/s40265-014-0218-4
- FDA. Clinical pharmacology biopharmaceutics review(s). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205437Orig1s000ClinPharmR.pdf. Accessed November 21, 2013.
- FDA. M9 biopharmaceutics classification system-based biowaivers. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m9-biopharmaceutics-classification-system-based-biowaivers. Accessed June 10, 2024.
- FDA. Bioavailability and bioequivalence studies submitted in NDAs or INDs. Available from: https://www.fda.gov/media/88254/download. Accessed June 10, 2024.
- EMA. Guideline on the investigation of bioequivalence. Available from: https://www.gmp-compliance.org/files/guidemgr/2016_EMEA_Bioequivalence.pdf. Accessed June 10, 2024.
- FDA. Draft guidance on apremilast. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Apremilast_Oral%20tablet_205437_RC09-15.pdf. Accessed September 18, 2015.
- Huh KY, Choi Y, Nissel J, et al. Pharmacokinetics and tolerability of apremilast in healthy Korean adult men. Clin Transl Sci. 2021;14(4):1505–1511. doi:10.1111/cts.13013
- Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica. 2011;41(12):1063–1075. doi:10.3109/00498254.2011.604745
- Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome--a Phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–1518. doi:10.1056/NEJMoa1408684
- Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738–746. doi:10.1016/S0140-6736(12)60642-4
- Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Behcet’s Syndrome. N Engl J Med. 2019;381(20):1918–1928. doi:10.1056/NEJMoa1816594
- Robichaud A, Tattersall FD, Choudhury I, Rodger IW. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology. 1999;38(2):289–297. doi:10.1016/s0028-3908(98)00190-7
- Abdulrahim H, Thistleton S, Adebajo AO, Shaw T, Edwards C, Wells A. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099–1108. doi:10.1517/14656566.2015.1034107